Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected in human 293T/ACE2 cells assessed as inhibition of viral infection pretreated the virus for 30 mins followed by viral infection measured after 48 hrs by by luciferase reporter gene assay
Inhibition of SARS-CoV-2 spike glycoprotein S expressed in human HEK293T cells cotransfected with pAAV-IRES-GFP assessed as inhibition of membrane fusion to African green monkey Vero E6 cells causing suppression of syncytium formation at 2 uM preincubated for 30 mins measured after 24 hrs by cell-cell fusion based fluorescence microscopy
Inhibition of SARS-COV2 ACE2 binding to spike glycoprotein S RBD domain preincubated for 31 mins with RBD followed by protein addition measured after 2.5 hrs by ELISA
Inhibition of SARS-CoV-2 spike glycoprotein expressed in HEK293T cells transfected with pAAV-CAG-HnCovS-RFP assessed as inhibition of membrane fusion to Huh-7 cells expressing hACE2 at 30 uM measured after 4 hrs by cell-cell fusion based fluorescence assay
Inhibition of SARS-CoV-2 spike glycoprotein expressed in HEK293T cells transfected with pAAV-CAG-HnCovS-RFP assessed as inhibition of membrane fusion to Huh-7 cells expressing hACE2 measured after 4 hrs by cell-cell fusion based fluorescence assay
Competitive inhibition of biotinylated heparin binding to His-tagged wild type SARS-COV-2 spike protein at 50 uM incubated for 300 sec by biolayer interferometry streptavidin sensor based assay
Competitive inhibition of biotinylated heparin binding to His-tagged wild type SARS-COV-2 spike protein incubated for 300 sec by biolayer interferometry streptavidin sensor based assay
Competitive inhibition of biotinylated heparin binding to His-tagged wild type SARS-COV-2 spike protein assessed inhibition constant incubated for 300 sec by biolayer interferometry streptavidin sensor based assay